Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 6/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411450 | 1.00 | PKM (0.66) | PKMPOLBLMNAMEN1KMT2A | |
| SCHEMBL29411421 | 0.72 | KMT2A (0.52) | POLBKMT2A | |
| SCHEMBL21045164 | 0.72 | KMT2A (0.52) | POLBKMT2A | |
| SCHEMBL21045101 | 0.71 | ALDH1A1 (0.51) | MEN1KMT2AGRIA4GAA | |
| SCHEMBL29411527 | 0.71 | ALDH1A1 (0.51) | MEN1KMT2AGRIA4GAA | |
| SCHEMBL21045166 | 0.70 | LMNA (0.52) | LMNAMEN1KMT2AGRIA4GAA | |
| SCHEMBL29411518 | 0.70 | LMNA (0.52) | LMNAMEN1KMT2AGRIA4GAA | |
| SCHEMBL10154069 | 0.68 | PKM (0.66) | PKMPOLBLMNAMEN1KMT2A | |
| SCHEMBL21045147 | 0.68 | GRIA4 (0.48) | MEN1KMT2AGRIA4 | |
| SCHEMBL29411437 | 0.68 | GRIA4 (0.48) | MEN1KMT2AGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PKM 1331/4885POLB 350/4885LMNA 2547/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | PKM 1331/4885POLB 350/4885LMNA 2547/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PKM 1331/4885POLB 350/4885LMNA 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.